Abstract

Driven by the need to find alternatives to control H. pylori infections, this work describes the development of chitosan-PMLA nanoparticulate systems as carriers for antimicrobial glycolipid. By using a simple ionic gelation method stable nanoparticle was obtained showing an encapsulation efficiency of 73.1 ± 1.3% and an average size of 217.0 ± 15.6 nm for rhamnolipids chitosan-PMLA nanoparticles (RL-CS-NPs). Glycolipid incorporation and particle size were correspondingly corroborated by FT-IR and TEM analysis. Rhamnolipids chitosan nanoparticles (RL-CS-NPs) presented the highest antimicrobial effect towards H. pylori (ATCC 26695) exhibiting a minimal inhibitory concentration of 132 µg/mL and a biofilm inhibition ability of 99%. Additionally, RL-CS-NPs did not interfere with human fibroblasts viability and proliferation under the tested conditions. The results revealed that the RL-CS-NPs were able to inhibit bacterial growth showing adequate cytocompatibility and might become, after additional studies, a valuable approach to fight H. pylori biofilm related-infections.

摘要

在寻找控制幽门螺杆菌感染的替代方法的需求驱使下，这项工作描述了壳聚糖-PMLA纳米颗粒系统作为抗微生物糖脂载体的发展。通过使用简单的离子凝胶法，获得了稳定的纳米颗粒，其对于鼠李糖脂壳聚糖-PMLA纳米颗粒（RL-CS-NPs）的封装效率为73.1±1.3％，平均尺寸为217.0±15.6 nm。通过FT-IR和TEM分析相应地证实了糖脂的掺入和粒径。鼠李糖脂壳聚糖纳米颗粒（RL-CS-NPs）对幽门螺杆菌的抗菌作用最高（ATCC 26695）的最低抑制浓度为132 µg / mL，生物膜抑制能力为99％。此外，在测试条件下，RL-CS-NPs不会干扰人类成纤维细胞的活力和增殖。结果表明，RL-CS-NPs能够抑制细菌生长，表现出足够的细胞相容性，经过进一步研究，可能成为对抗幽门螺杆菌生物膜相关感染的一种有价值的方法。